Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Finished Goods (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Finished Goods data on record, last reported at $65000.0 in Q3 2025.

  • For Q3 2025, Finished Goods fell 90.61% year-over-year to $65000.0; the TTM value through Sep 2025 reached $65000.0, down 90.61%, while the annual FY2024 figure was $173000.0, 57.28% down from the prior year.
  • Finished Goods reached $65000.0 in Q3 2025 per BTAI's latest filing, down from $73000.0 in the prior quarter.
  • Across five years, Finished Goods topped out at $1.4 million in Q2 2024 and bottomed at $65000.0 in Q3 2025.
  • Average Finished Goods over 4 years is $645000.0, with a median of $599500.0 recorded in 2022.
  • Peak YoY movement for Finished Goods: skyrocketed 314.33% in 2023, then tumbled 94.97% in 2025.
  • A 4-year view of Finished Goods shows it stood at $595000.0 in 2022, then plummeted by 31.93% to $405000.0 in 2023, then tumbled by 57.28% to $173000.0 in 2024, then plummeted by 62.43% to $65000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Finished Goods were $65000.0 in Q3 2025, $73000.0 in Q2 2025, and $178000.0 in Q1 2025.